Comprehensive NeuroScience Announces New Company Name and Tagline

MIRAMAR, Fla.--(BUSINESS WIRE)-- To better reflect its diverse therapeutic expertise, Comprehensive NeuroScience, Inc. (CNS), a strategic clinical research organization delivering high-quality clinical development services from early proof-of-concept through commercialization, is pleased to announce its plans to roll out the new company name, Comprehensive Clinical Development, along with its tagline, “The Proof is in the Performance.” Under its new name and tagline, Comprehensive Clinical Development will continue to deliver superior quality CRO services in partnership with sponsors who can be confident that their projects will be done correctly and on time.

Comprehensive Clinical Development adopted the tagline, “The Proof is in the Performance,” as part of their ongoing commitment and ability to advance compounds quickly and efficiently. As a trusted partner, Comprehensive Clinical Development provides complete Phase I through Phase IV clinical and non-clinical development services to biopharmaceutical clients.

“Our decision to change the company name and tagline was the result of intense evaluation and ongoing strategy to better position Comprehensive Clinical Development and articulate our therapeutic depth and breadth,” stated Comprehensive Clinical Development President Ali Craig-Rodriguez. “The name and tagline changes better reflect who we are and what we provide; while our name may be changing, our unwavering commitment to our internal and external customers has not changed.”

Comprehensive Clinical Development offers full-service capabilities and therapeutic expertise in numerous indications, including, but not limited to, CNS, dermatology, diabetes, infectious disease, obesity, and postmenopausal women, and collects early efficacy data across these populations.

Offering CRO services both of developmental and clinical conduct, Comprehensive Clinical Development leverages the diversity of its service networks to provide biopharmaceutical clients with exceptional quality and cost-effective trial management. Along with early and late phase site clinical conduct, Comprehensive Clinical Development provides a full range of services from protocol writing through final clinical study reporting.

About Comprehensive Clinical Development
Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical development services in various therapeutic areas with an outstanding record for consistently delivering quality and success on time and within budget. Comprehensive Clinical Development holds a solid track record of collecting early efficacy data across various patient populations, and offers distinct capabilities in clinical research. Comprehensive Clinical Development also offers CRO services to provide biopharmaceutical clients exceptional quality and cost-effective trial management. For more information about Comprehensive Clinical Development, visit www.comprehensivecro.com.



CONTACT:

SCORR Marketing
Kelly Sladek, 308-237-5567
[email protected]

KEYWORDS:   United States  North America  Florida  Nebraska

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.